EPO mimetic peptides were designed to stimulate non-erythroid EPO-like activity without increasing hematocrit such as ARA290 that has been suggested to benefit human metabolic control and neuropathy69–71, raising the potential for EPO mimetics to treat obesity and metabolic syndromes. The gene discussed is EPO; the disease is metabolic syndrome.